Prevention of Infection in Indian Neonates - Phase I Observational Study

India, with one of the world's largest populations, continues to struggle with extremely high infant and neonatal mortality rates. Neonatal infection (sepsis) now accounts for 50 percent of deaths among community-born (and 20 percent of mortality among hospital-born) infants. This study is the first phase of a multi-phase project investigating interventions to prevent neonatal infection in India.

Study Overview

• Status: Completed
• Conditions: Sepsis

Detailed Description

Invasive bacterial infections encompass clinical diagnoses of septicemia, pneumonia, and meningitis. Together, these infections are termed "neonatal sepsis" and account for over half of the newborn deaths at the district and sub-district level in India. Sepsis is the most common (80-90 percent) primary diagnosis for admission in Indian hospitals. Phase 1 of this study is a prospective, epidemiologic study involving over 1,000 community-based and hospital populations of newborn infants. It includes identifying all infants born in study hospitals and those brought to the hospitals with suspected sepsis; obtaining blood cultures from these infants and identifying the sepsis-causing bacteria; screening of all bacterial strains isolated from blood cultures for antimicrobial resistance; collecting basic demographic, risk factor, and treatment data on each case; and developing a computer-based system/network for data management. A village-level surveillance system was put in place to identify women during their pregnancy; monitor pregnancy outcomes; and establish a mechanism for referral of all potentially septic infants to participating clinics or hospitals for evaluation, including the collection of blood cultures. Potential sources of bacteria causing sepsis will be identified using molecular epidemiologic techniques. This involves matching septic infants' blood isolates with other colonizing isolates obtained from screening skin, throat, and stool cultures in the infant and skin and vaginal cultures from their mothers.

• Study Type: Observational
• Enrollment (Actual): 1326

Contacts and Locations

Study Locations

• India
  • Orissa
    • Bhubaneswar, Orissa, India
      • Capital Hospital
    • Bhubaneswar, Orissa, India
      • Kalinga Hospital
    • Rourkela, Orissa, India
      • Ispat General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 1 month (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age <60 days
• A diagnosis of suspected sepsis/pneumonia, based on the presence of at least one of the following symptoms at admission: poor feeding/poor sucking, decreased activity/lethargy, fever, hypothermia, cyanosis, diarrhea, abdominal distension, seizures, apneic spells, sclerema, bleeding, jaundice, tachypnea, chest wall retractions, shock.
• Born in one of the participating hospitals or in village inside catchment area If the screening physician does not suspect sepsis, even in the presence of one or more of the above signs, the baby should not be enrolled.

Exclusion Criteria:

• The presence of major congenital anomalies A major congenital anomaly is defined as any malformation that is felt to be life-threatening or that requires surgical intervention. If the medical officer is uncertain whether an anomaly is life-threatening, he/she should not enroll the infant.

Study Plan

How is the study designed?

Design Details

• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Indian Neonates; All hospitalized neonates (all live born infants <60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.

Collaborators and Investigators

• Sponsor: NICHD Global Network for Women's and Children's Health
• Collaborators: National Cancer Institute (NCI); University of Maryland; All India Institute of Medical Sciences, New Delhi; National Institute of Dental and Craniofacial Research (NIDCR); Bill and Melinda Gates Foundation; National Center for Complementary and Integrative Health (NCCIH); Fogarty International Center of the National Institute of Health; RTI International; Global Network for Women's and Children's Health Research; TN Medical College, Mumbai; Department of Health and Family Welfare, Orissa; SCB Medical College, Cuttack; Capital Hospital, Bhubaneswar; Ispat General Hospital, Rourkela; Kalinga Hospital, Bhubaneswar
• Investigators: Principal Investigator: Pinaki Panigrahi, M.D., University of Maryland School of Medicine

Publications and helpful links

Helpful Links

• Global Network for Women's and Children's Health Research
• RTI International

Study record dates

Study Major Dates

• Study Start: July 1, 2003
• Study Completion (Actual): July 1, 2006

Study Registration Dates

• First Submitted: August 20, 2007
• First Submitted That Met QC Criteria: August 20, 2007
• First Posted (Estimate): August 21, 2007

Study Record Updates

• Last Update Posted (Estimate): July 31, 2014
• Last Update Submitted That Met QC Criteria: July 29, 2014
• Last Verified: July 1, 2014

More Information

Terms related to this study

• Keywords: Antibiotics; Sepsis; International; Maternal and child health; India; Neonatal; Global Network
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Sepsis
• Other Study ID Numbers: GN 07 Phase I; U01HD040574 (U.S. NIH Grant/Contract)